The presentation of positive safety and pharmacologic data from a GLP toxicology study for SAB-142 indicates that the company is making progress in the development of a potential treatment for autoimmune and inflammatory diseases. This news may increase investor confidence in SAB Biotherapeutics and have a positive short-term impact on the stock price.